I’m sorry shell, but how does allogenic vs autologous CAR-T...

I’m sorry shell, but how does allogenic vs autologous CAR-T cells impact whether we attack the multitude of antigens expressed form AML? Isn’t the idea of Omnicar, that we can choose multiple different binders and administer that to the patient, regardless if the CAR-T cell is auto or allo?

It doesn’t make sense to me that we have scrapped the collaboration unless we plan to put the AML trial on the back burner. Perhaps this means we are going to pursue one of our solid tumour targets as our first in human trial. If we can make a dent in solid tumours with our CAR-T therapy that will well and truly put us on the worlds radar.